FCP
NVS icon

Fidelis Capital Partners’s Novartis NVS Stock Holding History

Fidelis Capital Partners’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Sell
1,383
-12
-0.9% -$1.8K 0.01% 510
2026
Q1 		$213K Buy
+1,395
New +$214K 0.02% 474

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fidelis Capital Partners's NVS Position: Q2 2026 in Review

Fidelis Capital Partners reduced its Novartis (NVS) stake by 0.86% in Q2 2026, selling an estimated $1.8K and leaving 1,383 shares worth $217K. The position accounts for 0.01% of the portfolio, ranked #510.

Fidelis Capital Partners first reported a position in NVS in Q1 2026 and has held it in 2 quarters since. 1,614 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Fidelis Capital Partners held 1,383 shares of Novartis worth $217K as of Q2 2026.
  • Fidelis Capital Partners sold 12 Novartis shares in Q2 2026, an estimated $1.8K.
  • Novartis made up 0.01% of Fidelis Capital Partners's portfolio in Q2 2026, its #510 holding.
  • Fidelis Capital Partners first reported a position in Novartis in Q1 2026 and has held it in 2 quarters since.
  • 1,614 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.